Noelia Alvarez-Rivas
Overview
Explore the profile of Noelia Alvarez-Rivas including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
77
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Alvarez-Rivas N, Lugo-Rodriguez G, Maneiro J, Iniguez-Ubiaga C, Melero-Gonzalez R, Iglesias-Cabo T, et al.
Bone Rep
. 2024 May;
21:101772.
PMID: 38774264
Introduction: Tumor-induced osteomalacia (TIO), is a rare acquired paraneoplastic syndrome characterized by defective bone mineralization, caused by the overproduction of fibroblast growth factor 23 (FGF23) by a tumor. Material And...
2.
Genre F, Prieto-Pena D, Pulito-Cueto V, Ocejo-Vinyals J, Atienza-Mateo B, Munoz Jimenez A, et al.
Clin Exp Rheumatol
. 2023 Mar;
41(4):910-915.
PMID: 36912345
Objectives: Since interleukin-6 (IL-6) is a pivotal proinflammatory cytokine implicated in the pathogenesis of giant cell arteritis (GCA), we aimed to determine the potential association of the functional IL6 -174...
3.
Prieto-Pena D, Genre F, Pulito-Cueto V, Ocejo-Vinyals J, Atienza-Mateo B, Munoz Jimenez A, et al.
Clin Exp Rheumatol
. 2022 Dec;
41(4):864-869.
PMID: 36533991
Objectives: Two main different clinical phenotypes of giant cell arteritis (GCA) have been described, the classic cranial pattern and the extracranial large-vessel (LV) pattern. Since interferon gamma (IFNG) has shown...
4.
Prieto-Pena D, Remuzgo-Martinez S, Genre F, Ocejo-Vinyals J, Atienza-Mateo B, Munoz-Jimenez A, et al.
Clin Exp Rheumatol
. 2022 Mar;
40(4):727-733.
PMID: 35349405
Objectives: To determine whether functional vascular endothelial growth factor (VEGF) polymorphisms influence the expression of the clinical phenotype of giant cell arteritis (GCA). We also evaluated whether VEGF polymorphism is...
5.
Prieto-Pena D, Bernabeu P, Vela P, Narvaez J, Fernandez-Lopez J, Freire-Gonzalez M, et al.
Ther Adv Musculoskelet Dis
. 2021 Jul;
13:1759720X211020917.
PMID: 34211589
Objective: To assess the efficacy and safety of tocilizumab (TCZ) in Caucasian patients with refractory Takayasu's arteritis (TAK) in clinical practice. Methods: A multicenter study of Caucasian patients with refractory...
6.
Prieto-Pena D, Remuzgo-Martinez S, Ocejo-Vinyals J, Atienza-Mateo B, Genre F, Munoz-Jimenez A, et al.
Clin Exp Rheumatol
. 2021 Mar;
39 Suppl 129(2):21-26.
PMID: 33734973
Objectives: To determine if patients with the predominant extracranial large-vessel-vasculitis (LVV) pattern of giant cell arteritis (GCA) have a distinctive HLA-B association, different from that reported in biopsy-proven cranial GCA...
7.
Calderon-Goercke M, Castaneda S, Aldasoro V, Villa I, Moriano C, Romero-Yuste S, et al.
Semin Arthritis Rheum
. 2021 Feb;
51(2):387-394.
PMID: 33607384
Objective: To compare the efficacy and safety of TCZ in monotherapy (TCZ) vs. combined with conventional immunosuppressive drugs (TCZ) in Giant Cell Arteritis (GCA) in a clinical practice scenario. Methods:...
8.
Alvarez-Rivas N, Sang-Park H, Diaz Del Campo P, Fernandez-Castro M, Corominas H, Andreu J, et al.
Reumatol Clin (Engl Ed)
. 2020 May;
17(3):170-174.
PMID: 32451263
Objective: To evaluate the efficacy and safety of belimumab in patients with Primary Sjögren's syndrome (pSS). Methods: The search included manuscripts assessing the efficacy or safety of belimumab in patients...
9.
Calderon-Goercke M, Castaneda S, Aldasoro V, Villa I, Prieto-Pena D, Atienza-Mateo B, et al.
Clin Exp Rheumatol
. 2020 May;
38 Suppl 124(2):112-119.
PMID: 32441643
Objectives: A potential point of concern among clinicians is whether results derived from the clinical trials can be reasonably applied or generalised to a definable group of patients seen in...
10.
Calderon-Goercke M, Loricera J, Aldasoro V, Castaneda S, Villa I, Humbria A, et al.
Semin Arthritis Rheum
. 2019 Jan;
49(1):126-135.
PMID: 30655091
Objective: Tocilizumab (TCZ) has shown efficacy in clinical trials on giant cell arteritis (GCA). Real-world data are scarce. Our objective was to assess efficacy and safety of TCZ in unselected...